NCT05286892 Diabetes Learning in Virtual Environments Just in Time for Community Reentry
| NCT ID | NCT05286892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Louise Reagan |
| Condition | Diabetes Mellitus, Type 1 |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2023-04-30 |
| Primary Completion | 2026-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2023-04-30 with a primary completion date of 2026-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. Outcome variables will include recruitment assessments, participation, engagement, user experience, and measures proximally related to behavior change - e.g., diabetes knowledge, diabetes-related distress, diabetes self-care, and social support and clinical outcomes -e.g., glycemic control. Focus group interviewing will be conducted to evaluate acceptability among intervention group participants.
Eligibility Criteria
Inclusion Criteria: Individuals will be eligible to participate if they: 1. have Type 1 or 2 diabetes 2. are age 18 and older 3. can speak and understand English 4. have been released directly from one of five Connecticut prisons to supervised community housing or parole
Contact & Investigator
Lousie Reagan, PhD
PRINCIPAL INVESTIGATOR
University of Connecticut
Frequently Asked Questions
Who can join the NCT05286892 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05286892 currently recruiting?
Yes, NCT05286892 is actively recruiting participants. Contact the research team at louise.reagan@uconn.edu for enrollment information.
Where is the NCT05286892 trial being conducted?
This trial is being conducted at Storrs, United States, Storrs Mansfield, United States.
Who is sponsoring the NCT05286892 clinical trial?
NCT05286892 is sponsored by Louise Reagan. The principal investigator is Lousie Reagan, PhD at University of Connecticut. The trial plans to enroll 128 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.